JP2019522972A5 - - Google Patents
Info
- Publication number
- JP2019522972A5 JP2019522972A5 JP2018566905A JP2018566905A JP2019522972A5 JP 2019522972 A5 JP2019522972 A5 JP 2019522972A5 JP 2018566905 A JP2018566905 A JP 2018566905A JP 2018566905 A JP2018566905 A JP 2018566905A JP 2019522972 A5 JP2019522972 A5 JP 2019522972A5
- Authority
- JP
- Japan
- Prior art keywords
- monomer
- monomers
- oligonucleotide
- bna
- oligonucleotide according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022161723A JP2023024968A (ja) | 2016-07-05 | 2022-10-06 | 遺伝性障害の治療のための改善された特徴を有する二環式スキャフォールド部分を含むプレmRNAスプライススイッチング又は調節オリゴヌクレオチド |
| JP2024037011A JP2024102041A (ja) | 2016-07-05 | 2024-03-11 | 遺伝性障害の治療のための改善された特徴を有する二環式スキャフォールド部分を含むプレmRNAスプライススイッチング又は調節オリゴヌクレオチド |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16177973 | 2016-07-05 | ||
| EP16177973.1 | 2016-07-05 | ||
| PCT/EP2017/066845 WO2018007475A1 (en) | 2016-07-05 | 2017-07-05 | Pre-mrna splice switching or modulating oligonucleotides comprising bicyclic scaffold moieties, with improved characteristics for the treatment of genetic disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022161723A Division JP2023024968A (ja) | 2016-07-05 | 2022-10-06 | 遺伝性障害の治療のための改善された特徴を有する二環式スキャフォールド部分を含むプレmRNAスプライススイッチング又は調節オリゴヌクレオチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019522972A JP2019522972A (ja) | 2019-08-22 |
| JP2019522972A5 true JP2019522972A5 (cg-RX-API-DMAC7.html) | 2024-07-05 |
| JP7817791B2 JP7817791B2 (ja) | 2026-02-19 |
Family
ID=56360269
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018566905A Active JP7817791B2 (ja) | 2016-07-05 | 2017-07-05 | 遺伝性障害の治療のための改善された特徴を有する二環式スキャフォールド部分を含むプレmRNAスプライススイッチング又は調節オリゴヌクレオチド |
| JP2022161723A Pending JP2023024968A (ja) | 2016-07-05 | 2022-10-06 | 遺伝性障害の治療のための改善された特徴を有する二環式スキャフォールド部分を含むプレmRNAスプライススイッチング又は調節オリゴヌクレオチド |
| JP2024037011A Pending JP2024102041A (ja) | 2016-07-05 | 2024-03-11 | 遺伝性障害の治療のための改善された特徴を有する二環式スキャフォールド部分を含むプレmRNAスプライススイッチング又は調節オリゴヌクレオチド |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022161723A Pending JP2023024968A (ja) | 2016-07-05 | 2022-10-06 | 遺伝性障害の治療のための改善された特徴を有する二環式スキャフォールド部分を含むプレmRNAスプライススイッチング又は調節オリゴヌクレオチド |
| JP2024037011A Pending JP2024102041A (ja) | 2016-07-05 | 2024-03-11 | 遺伝性障害の治療のための改善された特徴を有する二環式スキャフォールド部分を含むプレmRNAスプライススイッチング又は調節オリゴヌクレオチド |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20180028554A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3481955A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7817791B2 (cg-RX-API-DMAC7.html) |
| KR (4) | KR20230175312A (cg-RX-API-DMAC7.html) |
| CN (2) | CN109757108A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2017291960B2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3029772A1 (cg-RX-API-DMAC7.html) |
| IL (3) | IL301091A (cg-RX-API-DMAC7.html) |
| MX (2) | MX2018016253A (cg-RX-API-DMAC7.html) |
| RU (2) | RU2022107926A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018007475A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016040748A1 (en) | 2014-09-12 | 2016-03-17 | Ionis Pharmaceuticals, Inc. | Compositions and methods for detection of smn protein in a subject and treatment of a subject |
| AU2015367378A1 (en) | 2014-12-17 | 2017-06-15 | Proqr Therapeutics Ii B.V. | Targeted RNA editing |
| MA46427A (fr) | 2015-10-09 | 2018-08-15 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| EP3475424A1 (en) | 2016-06-22 | 2019-05-01 | ProQR Therapeutics II B.V. | Single-stranded rna-editing oligonucleotides |
| WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
| WO2018041973A1 (en) | 2016-09-01 | 2018-03-08 | Proqr Therapeutics Ii B.V. | Chemically modified single-stranded rna-editing oligonucleotides |
| EP3694530A4 (en) * | 2017-10-12 | 2021-06-30 | Wave Life Sciences Ltd. | COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES |
| WO2019190927A2 (en) * | 2018-03-26 | 2019-10-03 | Duke University | Splice-switching oligonucleotides and methods of use |
| JP2021521140A (ja) | 2018-04-12 | 2021-08-26 | ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. | オリゴヌクレオチド組成物及びその使用方法 |
| CA3098624A1 (en) * | 2018-05-11 | 2019-11-14 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| GB201808146D0 (en) | 2018-05-18 | 2018-07-11 | Proqr Therapeutics Ii Bv | Stereospecific Linkages in RNA Editing Oligonucleotides |
| EP3830259A4 (en) | 2018-08-02 | 2022-05-04 | Dyne Therapeutics, Inc. | MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| WO2020028832A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12331293B2 (en) * | 2018-11-02 | 2025-06-17 | Biomarin Technologies B.V. | Bispecific antisense oligonucleotides for dystrophin exon skipping |
| AU2019392928A1 (en) * | 2018-12-06 | 2021-06-17 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
| WO2020219820A1 (en) | 2019-04-25 | 2020-10-29 | Avidity Biosciences, Inc. | Nucleic acid compositions and methods of multi-exon skipping |
| WO2020252376A1 (en) * | 2019-06-13 | 2020-12-17 | Proqr Therapeutics Ii B.V. | Antisense rna editing oligonucleotides comprising cytidine analogs |
| WO2021046254A1 (en) * | 2019-09-04 | 2021-03-11 | Exicure, Inc. | Liposomal spherical nucleic acid (sna) constructs for splice modulation |
| US20230039928A1 (en) | 2019-12-23 | 2023-02-09 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for nucleotide deamination in the treatment of Stargardt disease |
| RU2738093C9 (ru) * | 2019-12-23 | 2020-12-29 | Общество с ограниченной ответственностью "Гелеспон" | Способ синтеза 2'-о-(2-метоксиэтил) тиофосфатного олигонуклеотида |
| AU2021225957A1 (en) | 2020-02-28 | 2022-09-08 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating SMN2 |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2022069511A1 (en) * | 2020-09-30 | 2022-04-07 | Biomarin Technologies B.V. | Antisense oligonucleotides targeting the exon 51 of dystrophin gene |
| WO2022232478A1 (en) | 2021-04-30 | 2022-11-03 | Sarepta Therapeutics, Inc. | Treatment methods for muscular dystrophy |
| WO2023283623A1 (en) | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
| EP4479535A1 (en) | 2022-02-14 | 2024-12-25 | ProQR Therapeutics II B.V. | Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia |
| EP4493693A1 (en) | 2022-03-17 | 2025-01-22 | Sarepta Therapeutics, Inc. | Phosphorodiamidate morpholino oligomer conjugates |
| US12071621B2 (en) * | 2022-04-05 | 2024-08-27 | Avidity Biosciences, Inc. | Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping |
| CN115806984B (zh) * | 2022-10-18 | 2023-10-10 | 昆明理工大学 | 环状rna及载体和载体的应用 |
| GB202215614D0 (en) | 2022-10-21 | 2022-12-07 | Proqr Therapeutics Ii Bv | Heteroduplex rna editing oligonucleotide complexes |
| KR20250113455A (ko) | 2022-11-24 | 2025-07-25 | 프로큐알 테라퓨틱스 Ⅱ 비.브이. | 유전성 hfe-혈색소침착증의 치료를 위한 안티센스 올리고뉴클레오티드 |
| GB202218090D0 (en) | 2022-12-01 | 2023-01-18 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency |
| WO2024121373A1 (en) | 2022-12-09 | 2024-06-13 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of cardiovascular disease |
| GB202300865D0 (en) | 2023-01-20 | 2023-03-08 | Proqr Therapeutics Ii Bv | Delivery of oligonucleotides |
| WO2024175550A1 (en) | 2023-02-20 | 2024-08-29 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease |
| GB202304363D0 (en) | 2023-03-24 | 2023-05-10 | Proqr Therapeutics Ii Bv | Chemically modified antisense oligonucleotides for use in RNA editing |
| JP2026510408A (ja) | 2023-03-24 | 2026-04-02 | プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ | 神経障害の処置のためのアンチセンスオリゴヌクレオチド |
| EP4688143A1 (en) | 2023-03-27 | 2026-02-11 | ProQR Therapeutics II B.V. | Antisense oligonucleotides for the treatment of liver disease |
| WO2024256620A1 (en) | 2023-06-16 | 2024-12-19 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of neurodegenerative disease |
| EP4774393A1 (en) | 2023-09-07 | 2026-07-15 | ProQR Therapeutics II B.V. | Antisense oligonucleotides for the treatment of metabolic disorders |
| CN122122297A (zh) * | 2023-09-13 | 2026-05-29 | 杭州颐东锐成生物科技有限公司 | 用于治疗杜氏肌营养不良症的组合物和方法 |
| AU2024379264A1 (en) | 2023-11-16 | 2026-05-14 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of classic galactosemia |
| AU2024402199A1 (en) | 2023-12-20 | 2026-07-16 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of huntington's disease |
| GB202404661D0 (en) | 2024-04-02 | 2024-05-15 | Proqr Therapeutics Ii Bv | Antisense oligoncleotides for the treatment of liver disease |
| GB202405143D0 (en) | 2024-04-11 | 2024-05-29 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of poly-q disease |
| WO2025224230A1 (en) | 2024-04-25 | 2025-10-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of fatty liver disease |
| GB202410081D0 (en) | 2024-07-11 | 2024-08-28 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of cardiovascular disease |
| WO2026022136A1 (en) | 2024-07-23 | 2026-01-29 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of metabolic disorders |
| WO2026060374A2 (en) | 2024-09-16 | 2026-03-19 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of neurological disorders |
| WO2026068781A1 (en) | 2024-09-30 | 2026-04-02 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of liver disease |
| WO2026080897A1 (en) | 2024-10-11 | 2026-04-16 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of chronic pain |
| WO2026093339A1 (en) | 2024-10-29 | 2026-05-07 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of peroxisome biogenesis disorders in the zellweger spectrum (pbd-zsd) |
| WO2026136663A1 (en) | 2024-12-18 | 2026-06-25 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of neurodegenerative disease |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6683173B2 (en) | 1998-04-03 | 2004-01-27 | Epoch Biosciences, Inc. | Tm leveling methods |
| US6656730B1 (en) | 1999-06-15 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Oligonucleotides conjugated to protein-binding drugs |
| US6653467B1 (en) * | 2000-04-26 | 2003-11-25 | Jcr Pharmaceutical Co., Ltd. | Medicament for treatment of Duchenne muscular dystrophy |
| EP1191097A1 (en) * | 2000-09-21 | 2002-03-27 | Leids Universitair Medisch Centrum | Induction of exon skipping in eukaryotic cells |
| AU2003225410A1 (en) * | 2003-03-21 | 2004-10-11 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
| ES2627917T3 (es) * | 2004-06-28 | 2017-08-01 | The University Of Western Australia | Oligonucleótidos no codificantes para la inducción de la omisión exónica y métodos de uso de los mismos |
| US20090312532A1 (en) | 2005-04-22 | 2009-12-17 | Van Deutekom Judith Christina | Modulation of exon recognition in pre-mrna by interfering with the binding of sr proteins and by interfering with secodary rna structure |
| EP2410053B2 (en) | 2006-10-18 | 2020-07-15 | Ionis Pharmaceuticals, Inc. | Antisense compounds |
| US20100016215A1 (en) * | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| NZ584793A (en) * | 2007-10-26 | 2012-05-25 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
| EP3133160B1 (en) * | 2008-10-24 | 2018-12-12 | Sarepta Therapeutics, Inc. | Exon skipping compositions for dmd |
| SI2607484T1 (sl) * | 2008-10-27 | 2016-11-30 | Biomarin Technologies B.V. | Metode in sredstva za učinkovito preskakovanje eksona 45 v pre-mRNA Duchennove mišične distrofije |
| CN102459595A (zh) * | 2009-04-24 | 2012-05-16 | 普罗森那技术公司 | 用于治疗dmd的包含肌苷的寡核苷酸 |
| EP2536738A4 (en) | 2010-02-08 | 2014-09-17 | Isis Pharmaceuticals Inc | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES OR SUFFERING IN CONNECTION WITH REPEAT EXTENSIONS |
| TWI541024B (zh) * | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | 反義核酸 |
| US9161948B2 (en) | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| WO2013030569A2 (en) | 2011-08-30 | 2013-03-07 | Michael John Gait | Peptides |
| CA2862628C (en) * | 2012-01-27 | 2021-08-24 | Prosensa Technologies B.V. | Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy |
| PT2841578T (pt) * | 2012-04-23 | 2017-08-10 | Biomarin Tech Bv | Resumo |
| AR091065A1 (es) * | 2012-05-18 | 2014-12-30 | Replicor Inc | Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral |
| CN104603271B (zh) * | 2012-07-03 | 2019-07-19 | 马林生物科技有限公司 | 用于治疗肌肉萎缩症患者的寡核苷酸 |
| WO2014010250A1 (en) | 2012-07-13 | 2014-01-16 | Chiralgen, Ltd. | Asymmetric auxiliary group |
| US8859754B2 (en) | 2012-07-31 | 2014-10-14 | Ased, Llc | Synthesis of deuterated ribo nucleosides, N-protected phosphoramidites, and oligonucleotides |
| WO2014093924A1 (en) | 2012-12-13 | 2014-06-19 | Moderna Therapeutics, Inc. | Modified nucleic acid molecules and uses thereof |
| WO2014112463A1 (ja) | 2013-01-15 | 2014-07-24 | 国立大学法人大阪大学 | スルホンアミド構造を有するヌクレオシドおよびヌクレオチド |
| WO2014126229A1 (ja) | 2013-02-18 | 2014-08-21 | 塩野義製薬株式会社 | 含窒素複素環構造を有するヌクレオシド及びヌクレオチド |
| EP3760720A1 (en) * | 2013-03-14 | 2021-01-06 | Sarepta Therapeutics, Inc. | Exon skipping compositions for treating muscular dystrophy |
| MX364814B (es) | 2013-03-15 | 2019-05-08 | Miragen Therapeutics Inc | Nucleosidos biciclicos unidos en puente. |
| HK1220154A1 (zh) * | 2013-03-15 | 2017-04-28 | Sarepta Therapeutics, Inc. | 改进的用於治疗肌营养不良的组合物 |
| CN105324119A (zh) * | 2013-06-16 | 2016-02-10 | 国立大学法人东京医科齿科大学 | 具有外显子跳跃效应的双链反义核酸 |
| TW201536329A (zh) * | 2013-08-09 | 2015-10-01 | Isis Pharmaceuticals Inc | 用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法 |
| EP3052632A4 (en) * | 2013-10-04 | 2017-03-29 | Rana Therapeutics, Inc. | Compositions and methods for treating amyotrophic lateral sclerosis |
| EP3119789B1 (en) | 2014-03-17 | 2020-04-22 | Ionis Pharmaceuticals, Inc. | Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom |
| WO2016017422A1 (ja) | 2014-07-31 | 2016-02-04 | 国立大学法人大阪大学 | 架橋型ヌクレオシドおよびヌクレオチド |
| RU2708237C2 (ru) | 2014-08-22 | 2019-12-05 | Общество с ограниченной ответственностью "НооГен" | Модифицированные олигонуклеотиды и способ их получения |
| US20170247695A1 (en) | 2014-10-17 | 2017-08-31 | Celgene Corporation | Isotopologues of smad7 antisense oligonucleotides |
| TWI787796B (zh) | 2015-05-04 | 2022-12-21 | 美商Cytomx生物製藥公司 | 抗cd71抗體類、可活化之抗cd71抗體類及使用彼等之方法 |
| KR102644053B1 (ko) | 2015-05-19 | 2024-03-06 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 펩티드 올리고뉴클레오티드 콘주게이트 |
| MA46427A (fr) * | 2015-10-09 | 2018-08-15 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| JP2018530560A (ja) * | 2015-10-09 | 2018-10-18 | サレプタ セラピューティクス, インコーポレイテッド | デュシェンヌ型筋ジストロフィーおよび関連障害の処置のための組成物および方法 |
-
2017
- 2017-07-05 AU AU2017291960A patent/AU2017291960B2/en active Active
- 2017-07-05 RU RU2022107926A patent/RU2022107926A/ru unknown
- 2017-07-05 KR KR1020237041258A patent/KR20230175312A/ko not_active Ceased
- 2017-07-05 WO PCT/EP2017/066845 patent/WO2018007475A1/en not_active Ceased
- 2017-07-05 CN CN201780042013.7A patent/CN109757108A/zh active Pending
- 2017-07-05 RU RU2018144875A patent/RU2769249C2/ru active
- 2017-07-05 CA CA3029772A patent/CA3029772A1/en active Pending
- 2017-07-05 IL IL301091A patent/IL301091A/en unknown
- 2017-07-05 MX MX2018016253A patent/MX2018016253A/es unknown
- 2017-07-05 KR KR1020237041259A patent/KR102824513B1/ko active Active
- 2017-07-05 EP EP17739231.3A patent/EP3481955A1/en active Pending
- 2017-07-05 KR KR1020197002990A patent/KR20190027373A/ko not_active Ceased
- 2017-07-05 KR KR1020267013245A patent/KR20260066185A/ko active Pending
- 2017-07-05 CN CN202511348833.1A patent/CN121271865A/zh active Pending
- 2017-07-05 JP JP2018566905A patent/JP7817791B2/ja active Active
- 2017-07-05 US US15/642,270 patent/US20180028554A1/en not_active Abandoned
- 2017-07-05 EP EP23175111.6A patent/EP4252845A3/en active Pending
- 2017-07-05 CA CA3273798A patent/CA3273798A1/en active Pending
-
2018
- 2018-12-19 MX MX2023006467A patent/MX2023006467A/es unknown
-
2019
- 2019-01-03 IL IL264084A patent/IL264084B2/en unknown
-
2022
- 2022-10-06 JP JP2022161723A patent/JP2023024968A/ja active Pending
-
2023
- 2023-03-06 US US18/179,064 patent/US20230330128A1/en active Pending
- 2023-06-27 AU AU2023204080A patent/AU2023204080B2/en active Active
-
2024
- 2024-03-11 JP JP2024037011A patent/JP2024102041A/ja active Pending
-
2025
- 2025-10-12 IL IL323882A patent/IL323882A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7803850B2 (ja) | 結合修飾オリゴマー化合物及びその使用 | |
| EP3368089B1 (en) | Nanoparticle formulations for delivery of nucleic acid complexes | |
| JP2025066730A (ja) | 分岐オリゴヌクレオチド | |
| JP7798836B2 (ja) | B型肝炎感染の治療用のPAPD5及びPAPD7 mRNAを低減させるための核酸分子 | |
| JP6626101B2 (ja) | GalNAcホスホラミダイト、その核酸結合体およびそれらの使用 | |
| RU2018144875A (ru) | Олигонуклеотиды, производящие переключение или модулирование сплайсинга пре-рнк и содержащие бициклические каркасные фрагменты, с улучшенными характеристиками для лечения генетических заболеваний | |
| CN119120476A (zh) | 用于抑制细胞中lpa的表达的核酸 | |
| WO2011139911A2 (en) | Lipid formulated single stranded rna | |
| EP3523437A1 (en) | Oligonucleotide compositions and methods thereof | |
| EP3728591B1 (en) | Gapmer oligonucleotides comprising a phosphorodithioate internucleoside linkage | |
| CN118984717A (zh) | Arnatar化合物和用于增强细胞摄取的方法 | |
| EP4671372A2 (en) | Translation-enhancing nucleic acid compounds: Upward regulation 1 coupled with ASO (ACT-UP1) and their uses | |
| JP2021502059A (ja) | 部分的に立体定義されたオリゴヌクレオチドのサブライブラリーを使用することによる、アンチセンスオリゴヌクレオチドの、改良された立体定義されたホスホロチオエートオリゴヌクレオチド変異体を同定するための方法 | |
| EP3728592B1 (en) | Oligonucleotides comprising a phosphorodithioate internucleoside linkage | |
| KR20250120382A (ko) | 유전자 침묵 기술로서 산재된 데옥시리보뉴클레오타이드를 갖는 짧은 이중체 rna 및 이의 용도 | |
| JP2025528464A (ja) | トレオース核酸アンチセンスオリゴヌクレオチドおよびその方法 | |
| JP6934695B2 (ja) | 核酸医薬とその使用 | |
| IL159759A (en) | History of oligoribonucleotide for deliberate inhibition of gene expression, medicinal preparations containing them, methods for their preparation and use | |
| US20260028630A1 (en) | Hybrid oligonucleotides | |
| US12454693B1 (en) | Nucleic acids for inhibiting expression of transferrin receptor 2 | |
| WO2019038228A1 (en) | OLIGONUCLEOTIDES FOR MODULATION OF TOM1 EXPRESSION | |
| CA3003267C (en) | Nanoparticle formulations for delivery of nucleic acid complexes | |
| CN122038397A (zh) | 一种化学修饰的siRNA分子及其应用 | |
| HK40110327A (en) | Asymmetric short duplex dna as a novel gene silencing technology and use thereof | |
| CN120285209A (zh) | 用于抑制病毒感染的寡核苷酸缀合物、药物组合物及其用途 |